Safety Considerations and Future Outlook As with all pharmacotherapy for obesity and T2D, establishing cardiovascular safety and demonstrating improvements in meaningful clinical outcomes will be essential, particularly as cardiovascular outcome trials have not yet been completed with multi-agonists (although data are expected soon for tirzepatide: SURPASS-CVOT [T2D] in 2025
Its not about the quantity of the food, said Anke Golde, senior director, R&D, with Ardent Mills
The type of fat that accumulates around our waistlines, hips, and deeply around our organs is known as White Adipose Tissue (WAT)
Many users prefer injecting in the evening so that any initial nausea occurs during sleep
Filled capsule enteric properties Retention of enteric properties of size #0 gelatin/HPMCAS capsules filled with EXE-loaded LBFs was evaluated using Apparatus B disintegration test: filled capsules placed in 0.1N HCl for 1 hour, followed by 1 hour in buffer pH 6.8